CTKB vs TXT · rev $92.3M vs P/E 19, rev $7.52B
Cytek Biosciences Inc (CTKB) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
Cytek Biosciences Inc (CTKB) is a medical devices company listed on US.
Textron Inc (TXT) is a aerospace & defense company listed on US.
Latest reported CTKB revenue for 2026-06-30 was $92.3M. Net income was -$31.0M. CTKB currently screens at market cap $421.8M.
Latest reported TXT revenue for 2026-07-04 was $7.52B. Net income was $468.0M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
CTKB currently screens at market cap $421.8M. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the CTKB and TXT stock pages for the full models.
Not investment advice.